Karyopharm Therapeutics Announces Management Change
“Mike has played an important role at Karyopharm over the past year including in our two successful financings which will support the development of our clinical pipeline and first commercial launch anticipated in the first half of 2019,” said
“It has been a privilege to work for Karyopharm and to have played a part in the growth of such an inspirational company,” said
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding our expectations for commericalization. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm’s control, that may cause actual events or results to differ materially from Karyopharm's current expectations due to risks and uncertainties inherent in Karyopharm’s business, including, without limitation: risks and uncertainties associated with the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities. The failure to meet expectations with respect to any of the foregoing matters may reduce Karyopharm's stock price. These and other risks are described under the caption “Risk Factors” in Karyopharm's Quarterly Report on Form 10-Q for the quarter ended
Vice President, Investor and Public Relations
857-297-2241 | email@example.com
Source: Karyopharm Therapeutics Inc.